[Insert Institution logo]

Physician Referral Letter

With minor adjustments, this could be sent as an email.

[DATE]

[DR. NAME]
[PRACTICE/FACILITY NAME]
[STREET]
[CITY, STATE] [ZIP CODE]

Dear Dr. [LAST NAME]:

We are pleased to announce that patients with suspected CAD can now be referred to [PRACTICE/FACILITY NAME] to receive a non-invasive CCTA ± HeartFlow FFR_{CT} Analysis. This is the first technology that uses standard coronary CTA scans to provide insights into anatomy and physiology in the diagnosis of CAD.

The CCTA ± HeartFlow FFR_{CT} process:

1. If a patient has suspected coronary artery disease, a clinician may order a standard CCTA scan to look at the anatomy for blockages.
2. If additional information is needed, a HeartFlow FFR_{CT} Analysis may be ordered to better understand the functional impact of the blockage (physiology/blood flow).
3. Leveraging advanced algorithms incorporating AI and computational fluid dynamics, the HeartFlow FFR_{CT} Analysis digital 3D model is built, showing how each blockage limits blood flow.
4. Within hours, the clinician receives the HeartFlow FFR_{CT} Analysis via a secure web interface and can assess, vessel by vessel, if sufficient blood flow is reaching the heart to better determine the best treatment path.

A CCTA ± FFR_{CT} first pathway has been supported by the ACC/AHA Chest Pain Guidelines and is already adopted by more than 725 hospitals worldwide, including 80% of the Top 50 Heart Hospitals in the US. New level 1 clinical evidence from the PRECISE trial, just presented as part of the Late-Breaking Clinical Sessions at AHA 2022, now shows that the CCTA ±FFR_{CT}-centered strategy is a frontline diagnostic pathway for patients with suspected CAD.

Please feel free to contact me at [PHONE NUMBER] or [EMAIL] for further information on the HeartFlow Analysis. I look forward to working together to improve the cardiovascular care for our patients.

Sincerely,
[NAME, TITLE]